News
AMRX
8.47
-5.89%
-0.53
Amneal Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Dow Jones · 6d ago
Amneal Pharmaceuticals Price Target Raised to $11.00/Share From $9.00 by Piper Sandler
Dow Jones · 6d ago
Piper Sandler Maintains Overweight on Amneal Pharmaceuticals, Raises Price Target to $11
Benzinga · 6d ago
Amneal Pharmaceuticals price target raised to $11 from $9 at Piper Sandler
TipRanks · 6d ago
Weekly Report: what happened at AMRX last week (1104-1108)?
Weekly Report · 6d ago
Barclays Reaffirms Their Buy Rating on Amneal Pharmaceuticals (AMRX)
TipRanks · 6d ago
Revenues Working Against Amneal Pharmaceuticals, Inc.'s (NASDAQ:AMRX) Share Price
Simply Wall St · 11/10 14:31
Amneal Pharmaceuticals Reports Q3 2024 Financial Results
TipRanks · 11/09 04:11
Bargain Priced Viatris Reports Strong Q3 Earnings Results
Seeking Alpha · 11/08 19:36
Amneal Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 11/08 16:22
Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
NASDAQ · 11/08 14:30
Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts
Benzinga · 11/08 14:30
Amneal Pharmaceuticals Profit Slips, Yet Beats Estimates; Backs Annual Outlook In Line With View
NASDAQ · 11/08 12:40
Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates
NASDAQ · 11/08 12:10
Amneal Pharmaceuticals Swings to 3Q Loss While Sales Climb
Dow Jones · 11/08 11:18
Amneal Pharmaceuticals backs FY24 adjusted EPS view 57c-63c, consensus 60c
TipRanks · 11/08 11:12
Amneal Reaffirms 2024 Revenue Guidance Of $2.7B-$2.8B And Adjusted EPS Of $0.57-$0.63 Versus Consensus Of $2.759B And $0.60, Respectively
Benzinga · 11/08 11:06
*Amneal Pharmaceuticals Backs 2024 Rev $2.70B-$2.80B >AMRX
Dow Jones · 11/08 11:01
AMNEAL PHARMACEUTICALS INC <AMRX.O> Q3 SHR VIEW $0.14, REV VIEW $696.8 MLN -- LSEG IBES DATA
Reuters · 11/08 11:00
*Amneal Pharmaceuticals 3Q Rev $702.5M >AMRX
Dow Jones · 11/08 11:00
More
Webull provides a variety of real-time AMRX stock news. You can receive the latest news about Amneal Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AMRX
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Generics segment includes a retail and institutional portfolio of over 270 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.